Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-14 |
2024-09 |
-0.33 |
N/A |
N/A |
N/A |
2024-08-08 |
2024-06 |
-0.34 |
-0.25 |
0.09 |
26.47% |
2024-05-09 |
2024-03 |
-0.21 |
-0.31 |
-0.1 |
-47.62% |
2024-05-09 |
2024-03 |
-0.21 |
N/A |
N/A |
N/A |
2024-03-14 |
2023-12 |
0 |
N/A |
N/A |
N/A |
2024-03-14 |
2023-12 |
0 |
-0.5 |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-08-13 |
HC Wainwright & Co. |
Upgrade |
Neutral |
Neutral |
2023-05-14 |
HC Wainwright & Co. |
Upgrade |
Neutral |
Neutral |
2023-03-19 |
HC Wainwright & Co. |
Downgrade |
Buy |
Neutral |
2023-02-22 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2022-11-13 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2022-08-14 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-05-22 |
BROWN BRIAN LEE |
Chief Financial Officer |
290.69K |
Conversion of Exercise of derivative security |
2024-05-22 |
DURENARD EUGENE A |
Director |
115.00K |
Conversion of Exercise of derivative security |
2024-05-22 |
EGAN DWIGHT H. |
Chief Executive Officer |
367.21K |
Conversion of Exercise of derivative security |
2024-05-22 |
MURPHY TED |
Director |
127.50K |
Conversion of Exercise of derivative security |
2024-05-22 |
NELSON JAMES B |
Director |
115.00K |
Conversion of Exercise of derivative security |
2024-05-22 |
SERBIN RICHARD S |
Director |
117.50K |
Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
1.78M |
1.98M |
5.79% |
2023-06-29 |
Renaissance Technologies, LLC |
653.70K |
725.61K |
2.12% |
2023-06-29 |
Blackrock Inc. |
506.51K |
562.22K |
1.65% |
2023-06-29 |
Geode Capital Management, LLC |
302.16K |
335.39K |
0.98% |
2023-06-29 |
Bridgeway Capital Management, Inc. |
272.90K |
302.92K |
0.89% |
2023-06-29 |
Bank Of New York Mellon Corporation |
145.62K |
161.64K |
0.47% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.28M |
1.42M |
4.15% |
2023-06-29 |
Vanguard Extended Market Index Fund |
444.78K |
493.70K |
1.44% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Fund |
272.90K |
302.92K |
0.89% |
2023-05-30 |
Fidelity Extended Market Index Fund |
165.22K |
180.09K |
0.54% |
2023-08-30 |
iShares Micro Cap ETF |
69.84K |
86.60K |
0.23% |
2023-05-30 |
Fidelity Total Market Index Fund |
53.59K |
58.41K |
0.17% |